Core Viewpoint - The public fund industry is experiencing a significant recovery in 2025 after a four-year downturn, with over 90% of active equity funds achieving positive returns this year, leading to increased confidence among fund managers and a revival in fund issuance [1][2]. Fund Performance - Active equity funds have seen an average return of over 13% year-to-date as of August 1, with a notable number of funds doubling their performance, including 17 funds that achieved over 140% returns [2]. - More than 800 active equity funds reached historical net asset value highs in the past month, indicating a strong recovery from previous losses [3]. Market Dynamics - The current market environment presents structural opportunities in sectors like humanoid robots, AI hardware, and innovative pharmaceuticals, which have contributed to the recovery of fund performance [2]. - Fund managers are increasingly focusing on high-growth sectors, with a shift from traditional sectors like real estate and bonds to equities, particularly in new economy sectors [3]. Fund Manager Behavior - Fund managers are showing a clear increase in risk appetite, with many raising their stock positions and concentrating their holdings in core stocks [5]. - Data shows that nearly 2,500 funds increased their stock positions and concentration in the second quarter, reflecting a significant shift in risk preference [5]. Fund Issuance Trends - The pace of new fund issuance has accelerated, with 149 new funds launched in July, matching the issuance rate from November 2022 [11]. - Notable funds like Dachen Insight Advantage raised 2.461 billion yuan in just eight days, marking the largest initial fundraising for active equity funds this year [9]. Investor Sentiment - Despite the positive performance, many investors remain cautious, with a tendency to redeem funds once they break even, indicating a need for trust rebuilding in active equity funds [1][11]. - The market is witnessing a preference for passive investment products over active equity funds, with high-performance products gaining more attention [11].

Core Viewpoint - The public fund industry is experiencing a significant recovery in 2025 after a four-year downturn, with over 90% of active equity funds achieving positive returns this year, leading to increased confidence among fund managers and a revival in fund issuance [1][3]. Fund Performance - Active equity funds have seen an average return of over 13% year-to-date, with a notable number of funds doubling their performance, including 17 funds that achieved over 140% returns as of July 29 [3]. - Despite some funds still recovering from previous losses, the short-term performance rebound is expected to support long-term growth [3]. - More than 800 active equity funds reached historical net asset value highs in the past month, indicating a strong recovery [3]. Fund Manager Sentiment - Fund managers are showing increased risk appetite, with many raising stock positions and focusing on core holdings [7][8]. - A significant number of funds have increased their stock positions by 5 to 8 percentage points, particularly in technology and growth sectors, as they anticipate improving profit growth in the latter half of the year [8][10]. Fund Issuance Trends - The positive performance has led to a noticeable acceleration in the issuance of new funds, particularly equity funds, with a significant increase in marketing efforts [12]. - In June, 155 new funds were established, marking a near-record high, and 135 funds were launched in July, indicating a robust recovery in the fund issuance market [13]. - Fund companies are rapidly increasing the pace of new fund launches to capitalize on the market rebound, with 149 new funds initiated in July alone [13]. Investor Behavior - Despite the positive performance, many investors remain cautious, with a tendency to redeem funds once they break even, indicating a trust gap that needs to be addressed for sustained growth [1][14]. - The demand for passive investment products is currently outpacing that for active equity funds, with high-performance products attracting more interest than stable ones [14].

Core Viewpoint - The public fund industry is experiencing a resurgence in 2025 after a prolonged period of stagnation, with over 90% of actively managed equity funds achieving positive returns this year, indicating a potential recovery in investor confidence [1][2]. Group 1: Fund Performance - Active equity funds have seen an average return exceeding 13% year-to-date, with a significant number of products doubling their performance, including 17 funds achieving returns over 140% as of July 29 [2]. - Over 800 active equity funds reached historical net asset value highs in the past month, reflecting a strong recovery in short-term performance [2][3]. - Despite some funds still recovering from previous losses, the overall performance improvement is expected to support long-term growth [2]. Group 2: Fund Manager Sentiment - Fund managers are increasingly optimistic, raising stock positions and focusing on core holdings, with some increasing their stock allocations by 5 to 8 percentage points [5][6]. - A notable shift in investment strategy is observed, with managers concentrating their portfolios, as seen in the increase of top ten holdings' concentration from around 50% to nearly 60% [6][7]. - Fund managers are favoring sectors with clear growth potential, particularly in technology and high-end manufacturing, as they anticipate improving profit growth in the latter half of the year [5][7]. Group 3: Fund Issuance and Market Dynamics - The positive performance of funds has led to a noticeable increase in the pace of new fund issuance, particularly in equity funds, with a significant rise in marketing efforts [8][9]. - In June, 155 new funds were established, marking a near-record high, with July seeing 135 new fund launches, indicating a robust recovery in the fund issuance market [9][10]. - Despite the overall positive trend, not all funds are equally favored, with passive investment products gaining more traction than actively managed equity funds [10].

Core Viewpoint - The "national team" has significantly increased its investment in ETFs and equity assets, with an estimated total investment exceeding 207 billion yuan in the first half of the year, reflecting a strategic move to stabilize the A-share market amid increased volatility [1][2][4]. Group 1: National Team's Investment Actions - In response to market fluctuations, the central financial institutions, including Central Huijin and China Guoxin, have actively increased their holdings in ETFs and other equity assets since April [2][3]. - Central Huijin Asset Management has become the largest institutional investor in the Huatai-PB CSI 300 ETF, increasing its holdings from 26.62 billion shares at the end of last year to 37.86 billion shares, raising its shareholding ratio from 29.78% to 40.26% [2][3]. - The total investment in ETFs by the national team in the first half of the year reached approximately 207.27 billion yuan, with significant contributions from various ETFs, including Huatai-PB, China Southern, and E Fund [4][3]. Group 2: Fund Managers' Adjustments - In the second quarter, over 57% of active equity funds increased their stock positions, with some funds raising their equity exposure by more than 30% [5][6]. - Notable fund managers, such as Zhang Kun, have adjusted their portfolios by increasing holdings in liquor stocks despite a general market downturn in the food and beverage sector [6][7]. - Liu Gesong has focused on increasing allocations to Hong Kong stocks and non-bank financials, while fund manager Ge Lan has concentrated on innovative pharmaceuticals, reducing exposure to traditional Chinese medicine and medical devices [7][8]. Group 3: Focus on Innovative Pharmaceuticals - The innovative pharmaceutical sector has attracted significant interest from fund managers, with many increasing their stakes in leading companies within this field [8]. - Ge Lan highlighted the ongoing advancements in innovative drug technologies and the increasing collaboration between domestic companies and multinational pharmaceutical firms, indicating a positive outlook for the sector [8].